--- title: "America Great Health says it cannot file its annual report by September 30, 2026" url: "https://aibio.space/news/america-great-health-says-cannot-file-annual-report-september-30-2026/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-09-25" section: "Distress" tickers: "OTC:AAGH" source: "https://www.sec.gov/Archives/edgar/data/1098009/000118518526004340/aaghnt10k063026.htm" summary: "The company filed a late-filing notice for the year ended June 30, 2026. It says it has not been able to compile the financial data for its Form 10-K." --- By the aibio.space news desk. Sources - [America Great Health NT 10-K (2026-09-25)](https://www.sec.gov/Archives/edgar/data/1098009/000118518526004340/aaghnt10k063026.htm) - [America Great Health 10-K (2026-04-10): business](https://www.sec.gov/Archives/edgar/data/1098009/000118518526001339/aagh10k063025.htm) - [America Great Health financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/1098009/000118518526001339/) [AAGH](https://aibio.space/companies/america-great-health/) 2026-09-25 # America Great Health says it cannot file its annual report by September 30, 2026 Tickers [AAGH](https://aibio.space/companies/america-great-health/) The company filed a late-filing notice for the year ended June 30, 2026. It says it has not been able to compile the financial data for its Form 10-K. ## Key facts - **Company**: America Great Health (OTC: AAGH) - **News type**: Distress - **Primary source**: [America Great Health NT 10-K (2026-09-25)](https://www.sec.gov/Archives/edgar/data/1098009/000118518526004340/aaghnt10k063026.htm) *The Capitol dome against a blue sky. Photo: Carol M Highsmith, CC0, via rawpixel. The picture shows the field, not the companies named.* ## The notice America Great Health ([AAGH](https://aibio.space/companies/america-great-health/)) filed a Form NT 10-K, also called a Form 12b-25, on September 25, 2026. The notice says the company will not be able to file its annual report on Form 10-K for the period ended June 30, 2026 by the September 30, 2026 deadline. In the narrative section the company states that it "has not been able to compile the requisite financial data and other narrative information" needed to finish the report without unreasonable effort and expense. It gives no other reason, names no auditor and describes no specific accounting problem. The company checked the box saying the 10-K will be filed on or before the 15th calendar day after the prescribed due date, which is the extension Rule 12b-25 allows. It did not attach an accountant's statement. Answering the questions in the second part of the form, it said all other periodic reports required during the preceding 12 months have been filed. It also said it does not anticipate any significant change in results of operations from the corresponding period for the last fiscal year, so the notice gives no explanation or estimate of results. The notice is signed by Mike Wang, President and Chief Executive Officer, who is also listed as the contact person. The company lists its principal executive office at 1609 W. Valley Blvd., #338, Alhambra, California. ## The filing record The notice does not describe the company's reporting history, but its own filings show that the annual report for the prior year, the year ended June 30, 2025, was filed on April 10, 2026. The notice itself says no other periodic reports are outstanding. ## The company America Great Health, formerly Crown Marketing, is a Wyoming corporation. A change of control was completed on January 19, 2017, when an investor group led by Mike Q. Wang bought 16,155,746,000 shares of common stock from the former majority shareholder, Jay Hooper. Before that the company sold electronic products directly to consumers and ceased that business as of December 31, 2016. Under the new group it says it focuses on the health industry. Its 10-K describes a series of arrangements. In June 2020 it agreed to acquire 51% of Purecell Group, an anti-aging medical institution in Australia, and issued 510,000,000 shares of common stock to Purecell's nominated trustee on April 6, 2021. Because the company does not have significant control over Purecell, it accounts for the stake as an equity investment. In December 2020 a California subsidiary agreed with Brilliant Healthcare Limited to form a stem cell joint venture in China, with the company to invest US$4.2 million for a 60% interest. The venture was set up in Hainan in June 2021, and the first investment was $50,000, paid on July 9, 2021. In November 2021 the company formed GOF Biotechnologies Inc., which it says is 75% owned by the company, with 25% held by Men Hwei, Tsai. It signed a consulting agreement that month with Dr. Kevin Buckman to advise the board on a new drug approval process for oral insulin and Amylase X, paid in part with a warrant to purchase 500,000 shares at $0.01 per share. The company also has a cooperation agreement with Dr. David Tsai on anti-cancer peptides, oral insulin and related technology, and says that several patents are in the application process and several products are being readied for production. ## Financial position The company's financial scale is small. For the fiscal year ended June 30, 2025, it reported revenue of $391,743, up from $294,670 a year earlier, and a net loss of $719,119, compared with a net loss of $1.2 million for fiscal 2024. Cash used in operations was $332,862, against $615,627 the year before. Cash and cash equivalents were $44,056 at June 30, 2025, and $29,346 at March 31, 2026, according to its quarterly report. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story AAGH America Great Health OTC ยท United States Open the starter desk ## More in Distress Distress ### [Mineralys takes ownership of lorundrostat patents but keeps Tanabe milestone debts](https://aibio.space/news/mineralys-takes-ownership-lorundrostat-patents-but-keeps-tanabe/) Oct 29, 2026 Distress ### [Bristol Myers Squibb drops Prothena's PRX019, ending up to $617.5 million in milestones](https://aibio.space/news/bristol-myers-squibb-drops-prothenas-prx019-ending-up-617-5-million/) Oct 29, 2026 Distress ### [LENZ Therapeutics reorganizes to cut 2027 operating expenses by more than 50%](https://aibio.space/news/lenz-therapeutics-reorganizes-cut-2027-operating-expenses-more-50/) Oct 28, 2026 --- Source page: https://aibio.space/news/america-great-health-says-cannot-file-annual-report-september-30-2026/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "America Great Health says it cannot file its annual report by September 30, 2026", 2026-09-25, https://aibio.space/news/america-great-health-says-cannot-file-annual-report-september-30-2026/